S&P Futures
4,212.25 +2.25 (+0.05%) Dow Futures
33,291.00 +31.00 (+0.09%) Nasdaq Futures
13,398.50 +6.50 (+0.05%) Russell 2000 Futures
1,970.30 +0.80 (+0.04%) Crude Oil
91.48 -0.45 (-0.49%) Gold
1,807.30 -6.40 (-0.35%)
Akari Therapeutics, Plc (AKTX)
Chart Events
Performance Outlook
| Previous Close | 1.5000 |
| Open | 1.5500 |
| Bid | 1.4200 x 1000 |
| Ask | 1.7000 x 900 |
| Day's Range | 1.5500 - 1.6000 |
| 52 Week Range | 0.7500 - 1.8800 |
| Volume | |
| Avg. Volume | 77,691 |
| Market Cap | 94.365M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4060 |
| Earnings Date | Sep 20, 2022 - Sep 26, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AKTX
Related Research
- Akari Therapeutics PlcDaily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 months agoArgus Research
- GlobeNewswire
Akari Therapeutics Narrows Pipeline Focus
NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), with Part A data expected in the first half of 2023
- Simply Wall St.
Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatmentsNew PK measurements indicate the half-life within the eye of intravitreally injected early generation PAS-nomacopan (also referred to as PAS600 nomacopan) in a standard ophthalmic pre-clinical model can be accurately predicted; result
